Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of bronchiectasis in adults

Alan F Barker, MD
Section Editors
James K Stoller, MD, MS
Talmadge E King, Jr, MD
Deputy Editor
Helen Hollingsworth, MD


Bronchiectasis is a syndrome of chronic cough and daily viscid sputum production associated with airway dilatation and bronchial wall thickening. Multiple conditions are associated with the development of bronchiectasis, but all require an infectious insult and usually also impairment of drainage, airway obstruction, and/or a defect in host defense.

Of the broad spectrum of causes of noncystic fibrosis bronchiectasis, only a few respond to direct treatment (eg, certain immunodeficiencies, nontuberculous mycobacterial infection, allergic bronchopulmonary aspergillosis). Instead, treatment of bronchiectasis is aimed at controlling infection, reducing inflammation, and improving bronchial hygiene [1,2]. Surgical extirpation of affected areas may be useful in selected patients.

The treatment of bronchiectasis will be reviewed here. The diagnosis and treatment of cystic fibrosis and the clinical manifestations and diagnosis of bronchiectasis are discussed separately. (See "Cystic fibrosis: Clinical manifestations and diagnosis" and "Cystic fibrosis: Overview of the treatment of lung disease" and "Cystic fibrosis: Antibiotic therapy for lung disease" and "Clinical manifestations and diagnosis of bronchiectasis in adults".)


For most causes of bronchiectasis, treatment of the underlying disease is not possible, as the bronchiectasis is a manifestation of scarring that resulted from a prior injury or infection (eg, severe pneumonia) or a result of an ongoing problem with secretion clearance that does not have a specific treatment (eg, primary ciliary dysfunction). However, some disease processes can be controlled to prevent further scarring. The evaluation and diagnosis of the underlying causes of bronchiectasis are discussed separately (table 1 and table 2 and table 3). (See "Clinical manifestations and diagnosis of bronchiectasis in adults".)

Examples of disease processes in which specific therapies may prevent progression of bronchiectasis include the following:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 15, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1.
  2. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45:1446.
  3. Gao YH, Guan WJ, Xu G, et al. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study. Chest 2015; 147:1635.
  4. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277.
  5. Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15.
  6. Finch S, McDonnell MJ, Abo-Leyah H, et al. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann Am Thorac Soc 2015; 12:1602.
  7. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47:1113.
  8. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130:1503.
  9. Ip M, Shum D, Lauder I, et al. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993; 87:449.
  10. Judson MA, Chaudhry H, Compa DR, OʼDonnell AE. A Delphi study of pharmacotherapy for noncystic fibrosis bronchiectasis. Am J Med Sci 2014; 348:387.
  11. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015; 202:21.
  12. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33:312.
  13. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; :CD002007.
  14. Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004; 59:231.
  15. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209.
  16. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10:1754.
  17. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132:1565.
  18. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102:1494.
  19. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660.
  20. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309:1251.
  21. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309:1260.
  22. Rogers GB, Bruce KD, Martin ML, et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014; 2:988.
  23. Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014; 19:321.
  24. Shi ZL, Peng H, Hu XW, Hu JG. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm Pharmacol Ther 2014; 28:171.
  25. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014; 44:382.
  26. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481.
  27. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420.
  28. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183:491.
  29. Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39.
  30. Barker A, O’Donnell A, Thompson PJ, et al. Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB). Eur Respir J 2013; 42:877s.
  31. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2:738.
  32. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41:1107.
  33. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68:812.
  34. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189:975.
  35. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105:1831.
  36. Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014; :CD002996.
  37. Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9.
  38. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106:661.
  39. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69:1073.
  40. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144:215.
  41. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2014; :CD001289.
  42. Tam J, Nash EF, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013; :CD007168.
  43. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.
  44. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113:1329.
  45. Flude LJ, Agent P, Bilton D. Chest physiotherapy techniques in bronchiectasis. Clin Chest Med 2012; 33:351.
  46. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:1086.
  47. Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009; 64 Suppl 1:i1.
  48. Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141:461.
  49. Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014; :CD010327.
  50. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; :CD000996.
  51. Holme J, Tomlinson JW, Stockley RA, et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 2008; 32:1047.
  52. Kapur N, Chang AB. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; :CD006427.
  53. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014; 2:455.
  54. Tsang KW, Lam WK, Kwok E, et al. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J 1999; 14:1345.
  55. Fortunato GA, Machado MM, Andrade CF, et al. Prevalence of gastroesophageal reflux in lung transplant candidates with advanced lung disease. J Bras Pneumol 2008; 34:772.
  56. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; :CD006316.
  57. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26:4284.
  58. Mandal P, Sidhu MK, Kope L, et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med 2012; 106:1647.
  59. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60:943.
  60. Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial. Respir Res 2014; 15:44.
  61. Olveira G, Olveira C, Doña E, et al. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr 2016; 35:1015.
  62. Pomerantz M, Denton JR, Huitt GA, et al. Resection of the right middle lobe and lingula for mycobacterial infection. Ann Thorac Surg 1996; 62:990.
  63. Watanabe M, Hasegawa N, Ishizaka A, et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg 2006; 81:2026.
  64. Zhang P, Jiang G, Ding J, et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg 2010; 90:246.
  65. Agasthian T, Deschamps C, Trastek VF, et al. Surgical management of bronchiectasis. Ann Thorac Surg 1996; 62:976.
  66. Mitchell JD, Yu JA, Bishop A, et al. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg 2012; 93:1033.
  67. Balkanli K, Genç O, Dakak M, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg 2003; 24:699.
  68. Vallilo CC, Terra RM, de Albuquerque AL, et al. Lung resection improves the quality of life of patients with symptomatic bronchiectasis. Ann Thorac Surg 2014; 98:1034.
  69. Serasli E, Kalpakidis V, Iatrou K, et al. Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes. Int Angiol 2008; 27:319.
  70. Odell DD, Shah A, Gangadharan SP, et al. Airway stenting and tracheobronchoplasty improve respiratory symptoms in Mounier-Kuhn syndrome. Chest 2011; 140:867.
  71. Titman A, Rogers CA, Bonser RS, et al. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009; 9:1640.
  72. Hayes D Jr, Kopp BT, Tobias JD, et al. Survival in Patients with Advanced Non-cystic Fibrosis Bronchiectasis Versus Cystic Fibrosis on the Waitlist for Lung Transplantation. Lung 2015; 193:933.
  73. Wang Y, Yang HB. Effects of functional endoscopic sinus surgery on the treatment of bronchiectasis combined with chronic rhino-sinusitis. Acta Otolaryngol 2016; 136:860.
  74. Dupont M, Gacouin A, Lena H, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125:1815.
  75. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008; 133:468.
  76. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34:843.
  77. Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis: what end points to use? Clin Chest Med 2012; 33:329.
  78. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189:576.
  79. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007; 101:1390.
  80. Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43:1357.
  81. Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J 2016; 47:482.
  82. Phua J, Ang YL, See KC, et al. Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis. Intensive Care Med 2010; 36:638.
  83. Navaratnam V, Muirhead CR, Hubbard RB, De Soyza A. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. QJM 2016; 109:523.
  84. Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108:287.
  85. Chung WS, Lin CL, Lin CL, Kao CH. Bronchiectasis and the risk of cancer: a nationwide retrospective cohort study. Int J Clin Pract 2015; 69:682.
  86. Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48:632.
  87. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187:1118.
  88. McCullough AR, Ryan C, O'Neill B, et al. Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioural change techniques and stakeholder expert panels. BMC Health Serv Res 2015; 15:342.